This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nelson, E. C.
Right arrow Articles by Elisha, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nelson, E. C.
Right arrow Articles by Elisha, B. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1999, p. 957-959, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Molecular Basis of AmpC Hyperproduction in Clinical Isolates of Escherichia coli

E. C. Nelson1 and B. Gay Elisha1,2,*

Department of Medical Microbiology, University of Cape Town,1 and Groote Schuur Hospital,2 Cape Town, South Africa

Received 3 December 1998/Returned for modification 8 January 1999/Accepted 25 January 1999

DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter. Transcription from the strong promoter was 8- to 18-fold higher than that from the promoter from a susceptible isolate. RNA studies showed that mRNA stability does not play a role in the control of AmpC synthesis.

* Corresponding author. Mailing address: Department of Medical Microbiology, Medical School UCT, Anzio Rd., Observatory 7925, Cape Town, South Africa. Phone: (27) (21) 406 6378. Fax: (27) (21) 448 8153. E-mail: gelisha{at}medmicro.uct.ac.za.

Antimicrobial Agents and Chemotherapy, April 1999, p. 957-959, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Haldorsen, B., Aasnaes, B., Dahl, K. H., Hanssen, A.-M., Simonsen, G. S., Walsh, T. R., Sundsfjord, A., Lundblad, E. W. (2008). The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother 62: 694-702 [Abstract] [Full Text]  
  • Fernandez-Cuenca, F., Pascual, A., Martinez-Martinez, L. (2005). Hyperproduction of AmpC {beta}-lactamase in a clinical isolate of Escherichia coli associated with a 30 bp deletion in the attenuator region of ampC. J Antimicrob Chemother 56: 251-252 [Full Text]  
  • Tracz, D. M., Boyd, D. A., Bryden, L., Hizon, R., Giercke, S., Van Caeseele, P., Mulvey, M. R. (2005). Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT-PCR. J Antimicrob Chemother 55: 768-772 [Abstract] [Full Text]  
  • Mulvey, M. R., Bryce, E., Boyd, D. A., Ofner-Agostini, M., Land, A. M., Simor, A. E., Paton, S., the Canadian Hospital Epidemiology Committee, , the Canadian Nosocomial Infection Surveillance Pro, (2005). Molecular Characterization of Cefoxitin-Resistant Escherichia coli from Canadian Hospitals. Antimicrob. Agents Chemother. 49: 358-365 [Abstract] [Full Text]  
  • Doi, Y., Wachino, J.-i., Ishiguro, M., Kurokawa, H., Yamane, K., Shibata, N., Shibayama, K., Yokoyama, K., Kato, H., Yagi, T., Arakawa, Y. (2004). Inhibitor-Sensitive AmpC {beta}-Lactamase Variant Produced by an Escherichia coli Clinical Isolate Resistant to Oxyiminocephalosporins and Cephamycins. Antimicrob. Agents Chemother. 48: 2652-2658 [Abstract] [Full Text]  
  • Corvec, S., Caroff, N., Espaze, E., Giraudeau, C., Drugeon, H., Reynaud, A. (2003). AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 52: 629-635 [Abstract] [Full Text]  
  • Siu, L. K., Lu, P.-L., Chen, J.-Y., Lin, F. M., Chang, S.-C. (2003). High-Level Expression of AmpC {beta}-Lactamase Due to Insertion of Nucleotides between -10 and -35 Promoter Sequences in Escherichia coli Clinical Isolates: Cases Not Responsive to Extended-Spectrum-Cephalosporin Treatment. Antimicrob. Agents Chemother. 47: 2138-2144 [Abstract] [Full Text]  
  • Tenover, F. C., Raney, P. M., Williams, P. P., Rasheed, J. K., Biddle, J. W., Oliver, A., Fridkin, S. K., Jevitt, L., McGowan, J. E. Jr. (2003). Evaluation of the NCCLS Extended-Spectrum {beta}-Lactamase Confirmation Methods for Escherichia coli with Isolates Collected during Project ICARE. J. Clin. Microbiol. 41: 3142-3146 [Abstract] [Full Text]  
  • Oliver, A., Weigel, L. M., Rasheed, J. K., McGowan, J. E. Jr., Raney, P., Tenover, F. C. (2002). Mechanisms of Decreased Susceptibility to Cefpodoxime in Escherichia coli. Antimicrob. Agents Chemother. 46: 3829-3836 [Abstract] [Full Text]  
  • Brinas, L., Zarazaga, M., Saenz, Y., Ruiz-Larrea, F., Torres, C. (2002). {beta}-Lactamases in Ampicillin-Resistant Escherichia coli Isolates from Foods, Humans, and Healthy Animals. Antimicrob. Agents Chemother. 46: 3156-3163 [Abstract] [Full Text]  
  • Corvec, S., Caroff, N., Espaze, E., Marraillac, J., Reynaud, A. (2002). -11 Mutation in the ampC Promoter Increasing Resistance to {beta}-Lactams in a Clinical Escherichia coli Strain. Antimicrob. Agents Chemother. 46: 3265-3267 [Abstract] [Full Text]  
  • Sabate, M., Miro, E., Navarro, F., Verges, C., Aliaga, R., Mirelis, B., Prats, G. (2002). {beta}-Lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). J Antimicrob Chemother 49: 989-997 [Abstract] [Full Text]  
  • Perez-Perez, F. J., Hanson, N. D. (2002). Detection of Plasmid-Mediated AmpC {beta}-Lactamase Genes in Clinical Isolates by Using Multiplex PCR. J. Clin. Microbiol. 40: 2153-2162 [Abstract] [Full Text]  
  • Philippon, A., Arlet, G., Jacoby, G. A. (2002). Plasmid-Determined AmpC-Type {beta}-Lactamases. Antimicrob. Agents Chemother. 46: 1-11 [Full Text]  
  • Martínez-Martínez, L., Conejo, M. C., Pascual, A., Hernández-Allés, S., Ballesta, S., Ramírez de Arellano-Ramos, E., Benedí, V. J., Perea, E. J. (2000). Activities of Imipenem and Cephalosporins against Clonally Related Strains of Escherichia coli Hyperproducing Chromosomal beta -Lactamase and Showing Altered Porin Profiles. Antimicrob. Agents Chemother. 44: 2534-2536 [Abstract] [Full Text]  
  • Caroff, N., Espaze, E., Gautreau, D., Richet, H., Reynaud, A. (2000). Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J Antimicrob Chemother 45: 783-788 [Abstract] [Full Text]  
  • Coudron, P. E., Moland, E. S., Thomson, K. S. (2000). Occurrence and Detection of AmpC Beta-Lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis Isolates at a Veterans Medical Center. J. Clin. Microbiol. 38: 1791-1796 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»